Thallous Chloride [Tl-201] Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

July 2016

Summary View


Risk of Extravasation and Tissue Damage (and Tissue Damage added)
  • Addition of:  Confirm intravenous patency before injection.


Postmarketing Experience (addition)
  • The following adverse reactions have been identified during post-approval use of Thallous Chloride Tl 201. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Injection site reactions and extravasation of Tl-201 have been reported: burning, pain, redness, swelling, warmth, and, in one case, tissue damage with chronic ulcer formation.


August 2011 

Summary View


  • The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.


Page Last Updated: 08/15/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English